Partner With Us

Following huge investment in the PD-1 and CTLA-4 space, the next generation of ICI is already showing great therapeutic promise, and as such, there has been an explosion in investment from biopharma leaders.

As TIGIT efforts are scaled, senior decision-makers are actively seeking partners with reliable and scientifically robust solutions to aid TIGIT development, such as tumor models, antibody manufacturing, companion diagnostics, biomarker platforms, as well as CRO partners.

Can you provide a solution to overcome the immune-oncology field's key challenges to help catapult TIGIT therapies to the clinic?

Email to learn more.

This is your opportunity to:

ttigit_-_monthly_touchpoints (1)

Touch base with
the industry to
stay updated on
key advances and
maintain lasting


Join the conversation
to better understand
industry challenges
and develop your
solutions early, as
the industry demand


Showcase your expertise in 1:1 networking sessions, securing your own 'virtual booth' and joining a panel to secure business in this early, rapidly growing space